HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zovirax launched OTC in Germany

This article was originally published in OTC Bulletin & The Rose Sheet

Executive Summary

German consumers are now able to buy GlaxoSmithKline (GSK) Consumer Healthcare’s Zovirax Duo cold-sore treatment without a prescription.

You may also be interested in...



German Expert Panel Opposes OTC Ibuprofen/Phenylephrine Combo, Hydrocortisone 1%

Two prescription-to-OTC switch applications rejected by Germany’s Expert Committee for Prescription: preparations containing a combination of ibuprofen and phenylephrine hydrochloride and hydrocortisone 1% for external use.

Germany’s OTC Market in 2018: Online Sees Double-Digit Growth, Bionorica’s Canephron Uno Tops New Launches

Germany's online channel continued to expand to expand in 2018, with OTC product sales via mail-order pharmacy growing almost 10-times faster than through bricks-and-mortar pharmacy. Meanwhile, GSK's Voltaren brand was top-seller through both channels and Bionorica's Canephron Uno was the best-selling launch during the 12 months. 

Avoiding ‘Kiss Killers’ – GSK Offers German Consumers New Oral Hygiene Products For The Festival Season

With Carnival season approaching in Germany, GlaxoSmithKline is helping German consumers to take care of their oral hygiene with new toothbrushes and its Zovirax Duo cold sore treatment. 

Topics

Latest News
UsernamePublicRestriction

Register

RS122081

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel